William Lewis, who serves as both chair and chief executive officer of Insmed Inc (NASDAQ:INSM), completed an open-market sale of 10,700 shares of the company's common stock on April 16, 2026, receiving $1,540,331 in proceeds. The shares were sold at prices between $142.99 and $145.79.
Also on April 16, Lewis exercised outstanding stock options to acquire 10,699 shares of Insmed common stock. Those option exercises were executed at strike prices of $30.46 and $17.16, with the total cost of the exercises recorded as $266,839.
After accounting for the sale and the option exercises, Lewis directly owns 301,185 shares of Insmed. He also retains an indirect interest in 233,924 shares held through a trust.
At the time of these filings, Insmed stock was trading at $144.48. The share price has fallen 7.8 percent over the past week, while returning 96.6 percent over the previous 12 months.
Independent analysis from InvestingPro indicates the stock appears overvalued relative to its Fair Value estimate; nonetheless, sell-side analysts have set price targets that span from $177 up to $243.
Recent analyst updates and clinical developments
Insmed has attracted a series of analyst revisions in light of recent corporate and clinical developments. Guggenheim raised its price target to $230 and kept a Buy rating, even as it projects first-quarter 2026 revenues of $286 million, a figure the firm notes is slightly below consensus expectations.
RBC Capital raised its price target to $216, citing constructive feedback from physicians about Brinsupri and an upbeat view on future prescribing trends for that product. Raymond James entered coverage with an Outperform rating and a $200 price target.
On the other hand, H.C. Wainwright reduced its target to $220 following the discontinuation of the brensocatib program after the Phase 2b CEDAR study failed to meet efficacy endpoints. Stifel retained a Buy rating with a $208 target while observing that the negative trial outcome was not unexpected given the absence of a clearly validated approach for this condition.
These updates underscore a bifurcated market response - some firms are shifting price targets higher on product-level optimism, while others are pulling back valuation or noting clinical setbacks.
Additional evaluation tools
The InvestingPro analysis referenced above also notes the availability of additional ProTips and comprehensive financial health metrics for investors seeking a deeper dive. Those resources are presented as part of the platform's valuation and equity-coverage materials.